A computational dynamic model of combination treatment for type II inhibitors with asciminib
J. Roadnight Sheehan, Astrid Silvia de Wijn, Ran Friedman
The paper develops a computational model to evaluate combination treatments of type II Abl1 inhibitors and asciminib, introducing ERICcombo to assess synergy and effectiveness at patient-relevant concentrations.
Protein Science · Jul 17, 2025Peer-reviewedCancer Biology